- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01703195
Magnetic Resonance Imaging of Gynecologic Malignancies Involving the Vagina
Study Overview
Status
Conditions
Detailed Description
If you agree to take part in this study, information will be collected from your medical record including your age, sex, and status of the disease.
For the MRI scans, you will receive a routine contrast drug by vein. Contrast drugs are used by doctors in order to see MRI images more clearly.
A modified MRI scan will performed right after your scheduled standard-of-care MRI scan. This modified MRI scan is the investigational scan. To complete the modified MRI scan, you will need to stay in the MRI scanner for about 8 extra minutes. It should take about 47 minutes total to complete both scans.
The way that researchers program the MRI machine and the order in which the images are taken is what is being modified for the investigational scan. These changes may help researchers capture better images.
Length of Study:
Your participation on this study will be over after the modified MRI scan is complete.
This is an investigational study. The standard-of-care MRI scan method is FDA approved and commercially available for the diagnosis of several diseases. The modified MRI scan method is being used in research only.
Up to 25 participants will be enrolled in this study. All will take part at MD Anderson.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All patients who have gynecologic malignancies involving the middle third and the distal third of the vagina who will be receiving radiation therapy
- Patients who have gynecologic malignancies involving the upper, middle and/or lower third of the vagina or are undergoing pelvic exenteration.
Exclusion Criteria:
- Pregnant patients
- Any implantable medical device that is not MRI compatible (e.g. pacemakers, defibrillators, pain pumps or insulin pumps)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Diffusion Weighted Magnetic Resonance Imaging (DWMR)
Patients receive Magnetic Resonance Imaging (MRI) and Diffusion Weighted Magnetic Resonance Imaging (DWMR) imaging pre-treatment and 4-6 weeks post-treatment.
|
Magnetic Resonance Imaging (MRI) obtained pre-treatment and 4-6 weeks post-treatment.
Other Names:
Diffusion Weighted Magnetic Resonance Imaging (DWMR) obtained pre-treatment and 4-6 weeks post-treatment.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Accuracy of Tumor Involvement Detection
Time Frame: 1 day
|
Location of tumor involvement determined based on pre-treatment imaging findings, where inferior margin of tumor marked on the MRI.
Tumor involved areas will then be evaluated by EUA, where fiducial markers will be placed and MRI images will be fused with the CT images to find if there is any discrepancy between the EUA and the DWI images.
The primary endpoint is the accuracy of tumor involvement detection (binary endpoint), where tumor invasion is defined as similar to that seen by EUA, in the anterior/posterior or the lateral walls of the vagina.
Similarity will be defined as the tumor margin seen on MRI being similar to what is seen on the EUA where the markers correspond to the margins defined on the MRI.
This will be defined as 5mm or less.
|
1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ability of Diffusion Weighted Magnetic Resonance Imaging (DWMR) to Assess Response to Radiation Therapy
Time Frame: 4 weeks after radiation therapy treatment
|
Secondary endpoints include quantitative measurements of discrepancies (or: quantitative measurement of the discrepancy) between DWMR and exam under anesthesia (EUA), agreement and difference between DWMR and other MR sequences (T2, DGE), and the ability of DWMR to assess response to therapy.
Summary statistics of results for each modality tabulated.
Accuracy, sensitivity, specificity, PPV, and NPV estimated along with corresponding 95% CIs.
Quantitative discrepancy measurements summarized using mean, SD, and range.
Difference and agreement between DWMR and other MR sequences assessed using the McNemar test and Kappa statistics, respectively.
|
4 weeks after radiation therapy treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Priya Bhosale, MD, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2011-0656
- NCI-2012-02054 (Registry Identifier: NCI CTRP)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vaginal Cancer
-
National Cancer Institute (NCI)CompletedRecurrent Cervical Cancer | Recurrent Vaginal Cancer | Stage IB Cervical Cancer | Stage II Vaginal Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage III Vaginal Cancer | Stage IVA Cervical Cancer | Stage IVA Vaginal Cancer | Stage IVB Cervical Cancer | Stage IVB... and other conditionsUnited States
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Advanced Vaginal Adenocarcinoma | Advanced Vaginal Adenosquamous Carcinoma | Advanced Vaginal Squamous Cell Carcinoma | Cervical Squamous Cell Carcinoma | Stage IB2 Cervical Cancer AJCC v6 and v7 | Stage II Cervical Cancer AJCC v7 | Stage... and other conditionsUnited States, Canada, Puerto Rico
-
Northwestern UniversityNational Cancer Institute (NCI)WithdrawnCervical Intraepithelial Neoplasia Grade 1 | Cervical Intraepithelial Neoplasia Grade 2 | Cervical Intraepithelial Neoplasia Grade 3 | Stage III Vulvar Cancer | Recurrent Cervical Cancer | Recurrent Vaginal Cancer | Recurrent Vulvar Cancer | Stage 0 Cervical Cancer | Stage 0 Vaginal Cancer | Stage 0 Vulvar... and other conditions
-
University of TorontoCanadian Cancer Trials GroupCompletedCervical Cancer | Vulvar Cancer | Vaginal Cancer | Uterine CancerCanada
-
Stanford UniversityNational Cancer Institute (NCI)CompletedCervical Cancer | Endometrial Cancer | Radiation Toxicity | Vaginal CancerUnited States
-
Memorial Sloan Kettering Cancer CenterCompleted
-
M.D. Anderson Cancer CenterCompleted
-
Leiden University Medical CenterDutch Cancer SocietyUnknownCervical Cancer | Gynecologic Cancer | Endometrial Cancer | Vaginal CancerNetherlands
-
Dana-Farber Cancer InstituteCompletedCervical Cancer | Vaginal Cancer | Uterine Cancer | Carcinoma of the VulvaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IB2 Cervical Cancer AJCC v8 | Stage II Cervical Cancer AJCC v8 | Stage IIA Cervical Cancer AJCC v8 | Stage IIA1 Cervical Cancer AJCC v8 | Stage IIA2 Cervical Cancer AJCC v8 | Stage IIB Cervical Cancer AJCC v8 | Stage III Cervical Cancer AJCC v8 | Stage IIIA Cervical Cancer AJCC v8 | Stage IIIB... and other conditionsUnited States
Clinical Trials on Magnetic Resonance Imaging (MRI)
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingProstate CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBrain NeoplasmUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingProstate Adenocarcinoma | Prostate CarcinomaUnited States
-
University of MichiganPhilips Healthcare; General ElectricCompleted
-
American College of RadiologyPennsylvania Department of HealthCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Recruiting
-
University of CincinnatiActive, not recruitingProstate CancerUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Healthy SubjectUnited States
-
University of California, San FranciscoTerminatedAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
Stanford UniversityTerminatedLaryngeal Neoplasms | Head and Neck Cancers | Larynx CancerUnited States